Pharma & Biotech - Page 10

The Trump administration has added nine pharmaceutical companies to its Most-Favored-Nation pricing program, bringing the total number of participating drugmakers to 26. President Donald J. Trump announced the expansion on August 31,

Lonza, widely regarded as the world’s leading contract development and manufacturing organisation, has named Samanta Cimitan as its new Chief Commercial Officer, Senior Vice President and Member of the Extended Executive Committee.

Cencora’s senior director of manufacturer operations and data services, Ameer Ali, is raising the alarm over the scale of disruption that the pharmaceutical industry faces in transitioning to the 12-digit NDC format.

PharmaEssentia has secured a significant regulatory milestone as the FDA approved a label expansion for its rare blood cancer drug Besremi, known generically as ropeginterferon alfa-2b-njft. The drug, first approved by the

Artis BioSolutions has launched a new Genetic Medicines Center of Excellence in Bilbao, Spain, expanding its integrated development and manufacturing capabilities. The facility strengthens the San Diego-based company’s position as a technology

Amgen and AstraZeneca’s Tezspire has delivered a significant phase 3 clinical win in eosinophilic esophagitis, intensifying competition with Sanofi and Regeneron’s Dupixent. The companies announced that the phase 3 CROSSING trial hit

The U.S. Court of Appeals for the Fifth Circuit has rejected a major pharmaceutical industry lawsuit challenging Medicare drug price negotiations under the Inflation Reduction Act. The appeals court affirmed a lower

Publicis Health has appointed Stephen Farquhar as its new chief executive officer, with the leadership transition taking effect on February 1. Farquhar steps into the role succeeding Alexandra von Plato, who has

Roche has been accelerating its obesity pipeline strategy through a series of high-value partnerships designed to compete in the fast-growing weight-loss drug market. The Swiss pharmaceutical giant struck a deal worth up

Teva Pharmaceuticals (TEVA) has emerged as the stalking horse bidder for bankrupt BioXcel Therapeutics’ neuroscience portfolio in a deal worth up to $125 million. Connecticut-based BioXcel filed for Chapter 11 bankruptcy protection